We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
Darlene Deptula-Hicks · Executive Officer · decision-maker
Scott Phillips · Executive Officer · decision-maker
Rachel Humphrey · Executive Officer, Director · decision-maker
Debanian Ray · Director
Careers mailbox is known
Jan 10, 2025
Raised a round Venture round $37.5M · SEC Form D
Jan 18, 2023
New executive Normunity Appoints Olga Granaturova as Chief Operating Officer and Chief Business Officer · businesswire.com
2020
Founded
Magnet Biomedicine is advancing monovalent molecular glue inhibitors (MGIs) and innovative protein degraders to engage disease drivers.
No named decision-maker yet.
Careers mailbox is known
Sep 27
Posted 2 roles Senior Scientist, Computational Chemistry, Senior Administrative Assistant
2 open
+2 this week
Our Adenovo™ platform and 100-million-variant library move us from discovery to impact. With THEO-260 as our lead programme, our world-class team is applying world-leading science to expand access to innovative therapies that promise lasting benefit.
No named decision-maker yet.
Careers mailbox is known
Jun 1
Won a grant $5.8M · CORDIS
Nenad Tomasevic · Executive Officer, Director · decision-maker
Kenneth Luehrsen · Director
Chandra Leo · Director
Andrew Schiff · Director
No careers mailbox known
Mar 16, 2022
Raised a round Venture round $62.5M · SEC Form D
2019
Founded
Breaking Barriers in Neurodegenerative Disease Treatment. At Vertero, our mission is to change the perception and treatment of neurodegenerative diseases to delay disease progression and preserve quality of life for patients as long as possible.
No named decision-maker yet.
Careers mailbox is known
STORM Therapeutics is a pioneer in the field of RNA epigenetics. We are an emerging biotechnology company in Cambridge, UK, focused on developing small molecule inhibitors of RNA-modifying enzymes for the treatment of cancer.
No named decision-maker yet.
Careers mailbox is known
At cellvie, we are pioneering Therapeutic Mitochondria Transplantation, a novel treatment approach aimed at the cellular energy metabolism.
No named decision-maker yet.
Careers mailbox is known
Delphia is pioneering activation lethality - a next-generation precision medicine approach that targets cancer's surprising vulnerability to oncogene overactivation.
No named decision-maker yet.
Careers mailbox is known
May 26
New executive Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer · delphiatx.com
Apr 8, 2025
Recognition Delphia Therapeutics Named to Boston Business Journal's 2025 Best Places to Work · delphiatx.com
May 2, 2024
Launched GENETIC ENGINEERING NEWS: The Upside Down: Delphia Therapeutics Launches to Treat Cancer with Activation Lethality · delphiatx.com
0 About Us Ann Lee-Karlon, Ph.D. Chief Executive Officer and President Read more Shyra Gardai, Ph.D.
Ann Lee-Karlon · Executive Officer, Director · decision-maker
Craig Lichtenstein · Executive Officer · decision-maker
Rami Hannoush · Executive Officer, Director · decision-maker
Mitchell Mutz · Executive Officer, Director · decision-maker
Careers mailbox is known
Jul 19, 2023
New executive EpiBiologics Appoints Ann Lee-Karlon as Chief Executive Officer and President, Extends Series A Financing to Over $70 Million · businesswire.com
Mar 21, 2022
Raised a round Venture round $73.1M · SEC Form D
2021
Founded
Light Horse is a small molecule drug discovery company that is leading the way in a.
No named decision-maker yet.
Careers mailbox is known
Committed to developing high-impact and differentiated therapies, with a focus on building a robust autoimmune disease and cancer pipeline. See how.
No named decision-maker yet.
No careers mailbox known
